Suchergebnisse - "Hong, David S"

PubPharm (25)

1

A phase i study of ixazomib and erlotinib in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2022

von Kato, S. | Adashek, J. | Subbiah, V. | +8

2

A phase i study of ixazomib and erlotinib in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2021

von Kato, S. | Adashek, J. | Subbiah, V. | +8

3

A phase i study of ixazomib and erlotinib in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2021

von Kato, S. | Adashek, J. | Subbiah, V. | +8

4

A phase i study of ixazomib and erlotinib in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2021

von Kato, S. | Adashek, J. | Subbiah, V. | +8

5

Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials

enthalten in: The oncologist | 2021

von Huey, R. | George, G. | Phillips, P. | +14

6

Long-term overall survival and prognostic score predicting survival : the IMPACT study in precision medicine

enthalten in: Journal of hematology & oncology | 2019

von Tsimberidou, A. | Hong, D. | Wheler, J. | +10

7

Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine

enthalten in: Journal of hematology & oncology | 2019

von Tsimberidou, A. | Hong, D. | Wheler, J. | +10

8

Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer

enthalten in: Investigational new drugs | 2018

von Kato, S. | Jardim, D. | Johnson, F. | +16

9

Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer

enthalten in: Investigational new drugs | 2017

von Kato, S. | Jardim, D. | Johnson, F. | +16

10

Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer

enthalten in: Investigational new drugs | 2017

von Kato, S. | Jardim, D. | Johnson, F. | +16